These results demonstrate that AC-NKs selectively recognize and engage with HER2-positive cancer cells via the action of trastuzumab, maintaining stable interactions over extended incubation periods, whereas interactions with HER2-negative cells remain minimal. This evidence concerns the gene ERBB2 and cancer.